Biologic dose escalation in inflammatory bowel disease in the United States

Nearly one-third of patients with IBD in this study escalated their biologic dose, which significantly increased their disease-related health care costs. These results demonstrate current challenges in long-term biologic therapy in IBD and highlight the ongoing need for further research into biologic management strategies to optimize IBD patient care and long-term outcomes, while containing costs.